Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07117877 | Sep 2025 → Aug 2026 overdue | ovarian carcinoma, refractory malignant neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07117877 ↗ |
| Known as | QL1706 | “Iparomlimab and Tuvonralimab (QL1706)” NCT07117877 ↗ |
| Route | Intravenous | “5mg/kg, i.v., q3w” NCT07117877 ↗ |